HAEK logo

HAEMATO AG Stock Price

HMSE:HAEK Community·€63.8m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

HAEK Share Price Performance

€11.80
1.00 (9.26%)
€11.80
1.00 (9.26%)
Price €11.80

HAEK Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Very low risk with weak fundamentals.

2 Risks
0 Rewards

HAEMATO AG Key Details

€260.8m

Revenue

€241.1m

Cost of Revenue

€19.7m

Gross Profit

€10.1m

Other Expenses

€9.6m

Earnings

Last Reported Earnings
Jun 30, 2023
Next Reporting Earnings
n/a
0
0%
0%
0%
View Full Analysis

About HAEK

Founded
1993
Employees
n/a
CEO
Thomas Ehmann
WebsiteView website
www.haemato.ag

HAEMATO AG, together with its subsidiaries, operates in the pharmaceutical sector in Germany. It operates through Specialty Pharma and Lifestyle & Aesthetics segments. The company engages in the development, acquisition, licensing, and distribution of prescription drugs and OTC products, special cosmetics, as well as dietary supplements. In addition, it provides pharmaceuticals in the areas of HIV/AIDS, neurology, oncology, and rheumatology diseases. Further, the company develops, manufactures, and distributes diagnostic tests under the HAEMATO brand, and cosmetics under the brand M1 SELECT, as well as supplies third party-products. It serves clinics, pharmacies, wholesalers, and medical test centers. HAEMATO AG was founded in 1993 and is based in Schönefeld, Germany. HAEMATO AG operates as a subsidiary of M1 Kliniken AG.

Recent HAEK News & Updates

Recent updates

No updates